

Docket No. 57094

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANT: M. Sakanaka et al.  
FILED: HEREWITH  
FOR: BRAIN CELL OR NERVE CELL-PROTECTING AGENTS  
COMPRISING MEDICINAL GINSENG

THE HONORABLE COMMISSIONER OF PATENTS AND TRADEMARKS  
WASHINGTON, DC 20231

SIR:

**PRELIMINARY AMENDMENT**

Applicants file the above-identified application herewith. Please amend the application as follows.

**IN THE CLAIMS**

Please cancel without prejudice claims 3-42, 44-63, 68-73, 75-80 and 82-87.

Please add the following new claims.

90. The composition of claim 2 wherein the cells are 1) cells in tissues or organs for transplanation or grafting; 2) cells in cultured kerationcyte sheets; 3) erythrocytes, leukocytes or platelets for transfusion; 4) erythrocytes; 5) stem cells; 6) embryonic stem cells; 7) cells in the skin; 8) cells in the circulatory system, or 9) cells in the immune system.

91. A medicinal or pharmaceutical comprising dihydroginsenoside Rb<sub>1</sub>, metabolites thereof or salts thereof.

92. The composition of claim 91 further comprising a pharmaceutically acceptable carrier.

93. A method for treating a mammal suffering from or susceptible to a disease causing apoptosis of cells or apoptosis-like cell death, comprising administering to the mammal a composition of claim 91.

94. A method for treating a mammal suffering from or susceptible to a disease causing apoptosis of cells or apoptosis-like cell death, comprising administering to the mammal a composition comprising ginseng, ginseng extracts, ginseng components, ginseng metabolites, or salts thereof.

95. The method of claim 94 wherein the ginseng components, metabolites thereof or salts thereof are crude saponin fractions, non-saponin fractions, purified saponins, constituents of saponin fractions or salts thereof.

96. The method of claim 94 wherein the ginseng or its extracts are red ginseng powder or its extracts.

97. A method for treating a mammal suffering from or susceptible to a disease causing apoptosis of cells or apoptosis-like cell death, comprising administering to the mammal a composition comprising ginseng, ginseng extracts, ginseng components, ginseng metabolites, or salts thereof.

98. The method of claim 97 wherein the ginseng components, metabolites thereof or salts thereof are crude saponin fractions, non-saponin fractions, purified saponins, constituents of saponin fractions or salts thereof.

99. The method of claim 97 wherein the ginseng or its extracts are red ginseng powder or its extracts.

M. Sakanaka et al.

Page 3

100. A method for treating a mammal suffering from or susceptible to brain or nervous diseases or disorders, comprising administering to the mammal a composition comprising ginseng, ginseng extracts, ginseng components, ginseng metabolites, or salts thereof.

101. The method of claim 100 wherein the ginseng components, metabolites thereof or salts thereof are crude saponin fractions, non-saponin fractions, purified saponins, constituents of saponin fractions or salts thereof.

102. The method of claim 100 wherein the ginseng or its extracts are red ginseng powder or its extracts.

103. The method of claim 100 wherein the mammal is suffering from cerebrovascular dementia, cerebral infarction or cerebral apoplexy.

104. A method for treating a mammal suffering from or susceptible to a cardiac disease, comprising administering to the mammal a composition comprising ginseng, ginseng extracts, ginseng components, ginseng metabolites, or salts thereof.

105. The method of claim 104 wherein the ginseng components, metabolites thereof or salts thereof are crude saponin fractions, non-saponin fractions, purified saponins, constituents of saponin fractions or salts thereof.

106. The method of claim 104 wherein the ginseng or its extracts are red ginseng powder or its extracts.

107. The method of claim 104 wherein the mammal is suffering from cerebrovascular dementia, cerebral infarction or cerebral apoplexy.

M. Sakanaka et al.  
Page 4

### REMARKS

For the sole purpose of reducing initial filing fees, claims 3-42, 44-63, 68-73, 75-80 and 82-87 have been cancelled without prejudice. Applicants expressly reserve the right to re-introduce the subject of any of those claims in the present application or a continuing application. Claims 90-107 also have been added. No new matter has been added by virtue of those new claims. For instance, basis for the new claims appears in the original claims.

Early consideration and allowance of the application are earnestly solicited

Respectfully submitted,



Peter F. Corless (Reg. 33,860)  
EDWARDS & ANGELL, LLP  
*Dike, Bronstein, Roberts & Cushman IP Group*  
P.O. Box 9169  
Boston, MA 02209  
(617) 523-3400